Bicara Therapeutics Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Bicara Therapeutics Inc. (BCAX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-11
- Bicara Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Bicara Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Bicara Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $413.00K.
- Bicara Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- Bicara Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.88M, a 354.72% increase from fiscal 2024.
- Bicara Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $413.00K, a 41.25% decline from fiscal 2023.
- Bicara Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $703.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $1.88M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.88M 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $1.88M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $413.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $413.00K derived: sum of 2 quarters · filed 2026-03-30 | $413.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $703.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $703.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |